Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) Operating Expenses (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Operating Expenses for 9 consecutive years, with $52.2 million as the latest value for Q4 2025.

  • For Q4 2025, Operating Expenses changed N/A year-over-year to $52.2 million; the TTM value through Dec 2025 reached $181.0 million, changed N/A, while the annual FY2025 figure was $181.0 million, 3.56% down from the prior year.
  • Operating Expenses hit $52.2 million in Q4 2025 for Soleno Therapeutics, up from $43.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $52.2 million in Q4 2025 and bottomed at $39.2 million in Q2 2025.